laim Form"), you may obtain copies of these documents by contacting: In re Hemispherx Biopharma, Inc. Litigation
, c/o Heffler, Radetich & Saitta, LLP, P.O. Box 58578, Philadelphia, PA 19102-8578. Copies of the Notice and Proof of Claim Form may also be downloaded from the Claims Administrator's website, www.heb.hrsclaims.com
. If you are a Class Member, in order to be eligible to share in the distribution of the Net Settlement Fund, you must submit a Proof of Claim Form no later than February 19, 2011, establishing that you are entitled to recovery.
If you have not obtained a copy of the Notice, you are urged to do so. If the proposed Settlement is approved, you will be bound by the Order and Final Judgment whether or not you submit a Proof of Claim Form.If you desire to be excluded from the Class, you must submit a request for exclusion by December 29, 2010, in the manner and form explained in the Notice. All Class Members who do not request exclusion from the Class will be bound by any judgment entered in the Action, including without limitation, the Order of Final Judgment and Dismissal with Prejudice, whether or not you timely submit a Proof of Claim Form.
Any objection to the proposed Settlement, Plan of Allocation, or application for attorneys' fees and reimbursement of litigation expenses must be filed with the Court and delivered to counsel for the parties not later than January 6, 2011 in the manner and form set forth in the Notice.
Inquiries, other than requests for the Notice and Proof of Claim Form, may be made to Co-Lead Counsel:
BERGER & MONTAGUE, P.C.
BROWER PIVENAttn: Sherrie R. Savett
A Professional Corporation1622 Locust Street
Attn: David A.P. BrowerPhiladelphia, PA 19103
488 Madison Ave., Eighth FloorNew York, NY 10022PLEASE DO NOT CONTACT THE COURT OR THE CLERK'S OFFICE REGARDING THIS NOTICE. &
Page: 1 2 3 Related medicine technology :1
|SOURCE Berger & Montague, P.C.; Brower Piven|
Copyright©2010 PR Newswire.
All rights reserved
. BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 20102
. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study3
. Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary4
. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results5
. EntreMed Receives Notice of NASDAQ Compliance6
. Caliper Life Sciences Third Quarter 2010 Financial Results Conference Call Notice7
. Incisive Surgical Issued Notice of Allowance for Key Absorbable Skin Stapler Patent8
. China Shenghuo Receives Notice from NYSE Amex LLC Regarding Listing Standards9
. KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Companys ADHD Prodrug Technology10
. KemPharm, Inc. Receives Notice of Issuance From USPTO on Patent Protecting Companys ADHD Prodrug Technology11
. Abviva Announces Notice of Canadian Patent for Technology Used in Breast Cancer Diagnostics and Therapeutics